WO1998055647A1 - Methode de diagnostic genotypique indirect de la migraine hemiplegique familiale de type 2 - Google Patents
Methode de diagnostic genotypique indirect de la migraine hemiplegique familiale de type 2 Download PDFInfo
- Publication number
- WO1998055647A1 WO1998055647A1 PCT/FR1998/001162 FR9801162W WO9855647A1 WO 1998055647 A1 WO1998055647 A1 WO 1998055647A1 FR 9801162 W FR9801162 W FR 9801162W WO 9855647 A1 WO9855647 A1 WO 9855647A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- markers
- hemiplegic migraine
- family
- marker
- gene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Definitions
- the present invention relates in particular to screening for predisposition as well as the diagnosis of familial hemiplegic migraine, hereinafter “MHF”, and the possibility of highlighting one or more genes involved in this condition.
- MHF familial hemiplegic migraine
- Hemiplegic migraine is a form of migraine with aura in which the aura has a unilateral motor deficit, usually associated with visual and sensitive symptoms, followed by migraine headaches (2, 3). In severe attacks, prolonged deficits, fever, confusion and coma, can occur but usually go away without sequelae (4).
- a linkage analysis conducted on one of these families not linked to chromosome 19 made it possible to locate a second gene responsible for MHF on chromosome 1.
- the susceptibility locus which will be referred to hereinafter as MHF2, (as opposed to the locus located on chromosome 19 known as MHF1), is located in the region Iq21-lq23 in an interval of 21 cM (centimorgan) (8) flanked by the two markers D1S2343 and D1 S2844.
- the markers mentioned in the present description are known, they are the markers of Genethon and the primers making it possible to demonstrate them are also known.
- a Lod-score greater than 3 was obtained in this first family with two markers, D1S2635 and D1S2705. Three other markers, D1S2343, D1S2707 and D1S2844 showed lod-scores greater than 2. All of these data made it possible to establish the existence of a second locus for MHF located on chromosome 1.
- Two other families of MHF among the 6 families tested for their binding to chromosome 1 were indeed linked to chromosome 1.
- the 4 remaining families were not linked to chromosome 1, thus demonstrating the existence of at least a third locus for MHF since these 4 families were also not linked to chromosome 19.
- the present invention relates to a method of indirect genotypic diagnosis of familial hemiplegic migraine type 2 in an individual characterized in that:
- This method can be applied in particular in the following two cases: • on the one hand, in front of a table of familial hemiplegic migraine, to highlight the fact that it is an MHF2, that is to say linked to chromosome 1, and which could justify specific treatments different from those applied in the case of MHF1 linked to chromosome 19,
- markers linked to the occurrence of MHF within the family of the individual is intended to denote the presence of one or more DNA sequences which are linked with the occurrence of the disorder in the family, some of these markers located in the previous locus are identified more precisely below.
- a marker which can be used in the method according to the present invention can be demonstrated by the binding analysis applied to DNA samples from family members, affected or not. This is a process which is known and which will therefore only be briefly recalled below.
- the first step is to establish the link between the gene responsible for the pathology and one or more markers. This study is conducted on families whose structure lends itself to this type of analysis, that is to say families in which the presence of familial hemiplegic migraine has been clearly established by clinical analyzes as complete as possible.
- microsatellites flanking highly polymorphic CA or GATA repeat units, these markers covering the interval in which the gene involved in the pathology is found, here the locus located between D1 S2343 and D! S2844.
- microsatellites flanking highly polymorphic CA or GATA repeat units, these markers covering the interval in which the gene involved in the pathology is found, here the locus located between D1 S2343 and D! S2844.
- the two markers mentioned above are the end markers but other markers could have been used, these in particular are the markers:
- the alleles are defined by the different sizes of the fragments amplified with the oligonucleotides corresponding to a given microsatellite.
- the most commonly used method consists, after having hybridized the primers corresponding to the microsatellite markers for example, to carry out an amplification by PCR or by any analogous method, then to separate the product from amplification, in particular by electrophoresis on acrylamide gel, then demonstrated by labeling with the polyCA or polyGATA type sequences as a probe for microsatellites.
- lod-score The so-called "lod-score” statistical analysis is a known statistical technique and it is commonly accepted that a lod-score greater than 3 unambiguously establishes the link between the pathology gene and the marker tested.
- a marker and a gene are very close (they are said to be linked), the portion of chromosome containing them will be transmitted as such to the descendants; on the other hand, if the marker is more distant, it may be separated from the gene during transmission (“crossing over”) and its presence is no longer necessarily associated with the presence of the defective gene.
- the method according to the invention can be implemented both in adults, in children and in the fetus as a prenatal diagnosis.
- PCR complementary metal-oxide-semiconductor
- the principle is to carry out several PCR reactions simultaneously from the same genomic DNA sample.
- the advantage is to save the reagents as well as the DNA to be typed, and reduce the risk of error by reducing the number of manipulations.
- the disclosure methods are known and will not be described in detail.
- a diagnostic protocol is given below on the basis of the polymo ⁇ hisms which have been described previously. Of course, any method of indirect genotypic diagnosis can be used.
- DNA is obtained from the various family members, each of whom has been studied clinically in order to demonstrate the existence or not of the disease in the individual in question.
- Nuclear DNA can, for example, be isolated from peripheral blood leukocytes, lymphoblastoid cells, cells from amniotic fluid, cultured or otherwise, treated appropriately.
- the confirmation of the link or the absence of link between the analyzed fragments and the MHF were the subject of a statistical analysis for which a link score higher than 3 establishes in an unambiguous way the link between the gene responsible for pathology and the marker tested.
- a positive lod-score but less than 3 can be obtained when linked to the MHF2 locus, due to the small size of the family explored.
- a calculation of the probability that the family is related can then be performed using the HOMOG method (12). This then makes it possible to determine the most informative microsatellites for the family in question.
- the diagnostic protocol for an individual at risk of a disease implements the information previously obtained: • we select the most informative markers for the family in question,
- the present invention also relates to the DNA sequence and the genes involved in MHF2.
- the localization of the MHF2 gene in fact makes it possible, through a functional cloning strategy, to identify this gene. It is possible to isolate the gene, in particular by:
- the present invention also relates to the DNA sequence located on the locus located between the markers D1 S2343 and
- D1S2844 and linked to the occurrence of familial hemiplegic migraine as well as the gene involved in the occurrence of hemiplegic migraine type 2 and located on a DNA according to the invention.
- the only figure shows schematically the pedigree of the 3 MHF families linked to chromosome Iq21-q23. Affected individuals are represented by blackened symbols, unaffected individuals are represented by empty symbols, when the status of the individual is unknown, the symbol is hatched, individuals with no information are crossed out.
- the position of the various markers in the region has also been shown.
- the alleles for the markers are represented for each individual, the blackened parts indicate regions which co-aggregate with the disease.
- the P family is a large Caucasian family of 3 generations from the north of France. Families C, D and V are from southern France, families H and N from central France and family W from northern Spain. A total of 102 subjects including 20 spouses were examined as part of this study.
- family P 12 members suffer from characteristic hemiplegic migraine attacks (2). In addition to the typical attacks, 5 of them suffered severe episodes in which hemiplegia was associated with fever, confusion and coma. In the other 6 pedigrees, 35 patients were identified fulfilling the criteria of the International Headache Society. The 47 subjects suffering from MHF had a normal neurological examination outside the attacks. These 47 members have been classified as affected.
- DNA is extracted from the blood of different individuals by known methods. 5 markers were chosen from the Genethon link map.
- the DNA was amplified by the PCR method using the PHC3 Techne device.
- the reactions are carried out in a final volume of 50 ⁇ l containing 200 ng of genomic DNA, 125 mM 4dNTP mixture, 1 x PCR buffer Cetus Taq polymerase, 1 U BRL Taq polymerase, 1 mM of each primer.
- the samples are treated for 30 temperature cycles (1 cycle, 94 ° C for 5 min; 28 cycles including a denaturation step at 92 ° C for 1 min and a fixing step at 55 ° C for 1 min and extension to 72 ° C for 1 min; the last cycle allows an extension to 72 ° C for 10 min).
- the samples are denatured for 5 minutes at 94 ° C.
- allelic frequency for each locus is obtained from the Genome Data Base. Analysis of the results 30 members of the P family were genotypes with 260 microsatellite markers covering all the chromosomes.
- the region where the MHF2 gene has been located contains two candidate genes for this condition, GLRK3 (15, 16, 17) which codes for a potassium channel, and CACNL1A6 (13, 14) which codes for a calcium channel.
- the invention also relates to the use of the hGLRK3 and CACNL1A6 genes for the detection of familial hemiplegic migraine.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002292795A CA2292795A1 (fr) | 1997-06-06 | 1998-06-08 | Methode de diagnostic genotypique indirect de la migraine hemiplegique familiale de type 2 |
EP98929511A EP0983390A1 (fr) | 1997-06-06 | 1998-06-08 | Methode de diagnostic genotypique indirect de la migraine hemiplegique familiale de type 2 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9707033A FR2764306B1 (fr) | 1997-06-06 | 1997-06-06 | Methode de diagnostic genotypique indirect de la migraine hemiplegique familiale de type 2 |
FR97/07033 | 1997-06-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998055647A1 true WO1998055647A1 (fr) | 1998-12-10 |
Family
ID=9507694
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1998/001162 WO1998055647A1 (fr) | 1997-06-06 | 1998-06-08 | Methode de diagnostic genotypique indirect de la migraine hemiplegique familiale de type 2 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0983390A1 (fr) |
CA (1) | CA2292795A1 (fr) |
FR (1) | FR2764306B1 (fr) |
WO (1) | WO1998055647A1 (fr) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2116633A1 (fr) * | 1994-02-28 | 1995-08-29 | Anne Marie Gisele Joutel | Methode de diagnostic de la migraine familiale hemiplegique (fhm) |
-
1997
- 1997-06-06 FR FR9707033A patent/FR2764306B1/fr not_active Expired - Fee Related
-
1998
- 1998-06-08 CA CA002292795A patent/CA2292795A1/fr not_active Abandoned
- 1998-06-08 EP EP98929511A patent/EP0983390A1/fr not_active Withdrawn
- 1998-06-08 WO PCT/FR1998/001162 patent/WO1998055647A1/fr not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2116633A1 (fr) * | 1994-02-28 | 1995-08-29 | Anne Marie Gisele Joutel | Methode de diagnostic de la migraine familiale hemiplegique (fhm) |
Non-Patent Citations (6)
Title |
---|
DIRIONG S ET AL: "CHROMOSOMAL LOCALIZATION OF THE HUMAN GENES FOR ALPHA1A, ALPHA1B, AND ALPHE1E VOLTAGE-DEPENDENT CA2+ CHANNEL SUBUNITS", GENOMICS, vol. 30, no. 3, 10 December 1995 (1995-12-10), pages 605 - 609, XP000647692 * |
DUCROS A ET AL.: "Mapping of a second locus for familial hemiplegic migraine to 1q21-q23 and evidence of further heterogeneity", ANNALS OF NEUROLOGY, vol. 42, no. 6, 1997, pages 885 - 890, XP002058761 * |
GYAPAY G ET AL: "THE 1993-94 GENETHON HUMAN GENETIC LINKAGE MAP", NATURE GENETICS, vol. 7, June 1994 (1994-06-01), pages 246 - 339, XP000644432 * |
JOUTEL A ET AL: "GENETIC HETEROGENEITY OF FAMILIAL HEMIPLEGIC MIGRAINE", AMERICAN JOURNAL OF HUMAN GENETICS, vol. 55, no. 6, December 1994 (1994-12-01), pages 1166 - 1172, XP000647696 * |
LESAGE F ET AL.: "Assignment of human G-protein-coupled inward rectifier K+ channel homolog GIRK3 gene to chromosome 1q21-q23", GENOMICS, vol. 29, 1995, pages 808 - 809, XP002058760 * |
OPHOFF R A ET AL: "GENETIC HETEROGENEITY OF FAMILIAL HEMIPLEGIC MIGRAINE", GENOMICS, vol. 22, no. 1, 1 July 1994 (1994-07-01), pages 21 - 26, XP000647632 * |
Also Published As
Publication number | Publication date |
---|---|
FR2764306B1 (fr) | 2001-08-10 |
CA2292795A1 (fr) | 1998-12-10 |
EP0983390A1 (fr) | 2000-03-08 |
FR2764306A1 (fr) | 1998-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Awata et al. | High frequency of aspartic acid at position 57 of HLA-DQ β-chain in Japanese IDDM patients and nondiabetic subjects | |
Coppieters et al. | Identity-by-descent–guided mutation analysis and exome sequencing in consanguineous families reveals unusual clinical and molecular findings in retinal dystrophy | |
Málaga-Trillo et al. | Linkage relationships and haplotype polymorphism among cichlid Mhc class II B loci | |
Moussa et al. | Molecular background of D‐negative phenotype in the Tunisian population | |
US20090186340A1 (en) | Gene Analysis | |
US8206911B2 (en) | Identification of the gene and mutation responsible for progressive rod-cone degeneration in dog and a method for testing same | |
AU2009275988B2 (en) | A genetic marker test for Brachyspina and fertility in cattle | |
WO1995024504A1 (fr) | Marqueurs genetiques utilises conjointement pour le diagnostic de la maladie d'alzheimer, methode et kit de diagnostic | |
EP0763136B1 (fr) | Procede et sondes pour la detection de marqueurs lies au locus des amyotrophies spinales infantiles | |
WO1998055647A1 (fr) | Methode de diagnostic genotypique indirect de la migraine hemiplegique familiale de type 2 | |
US7811761B2 (en) | Method for identifying progressive rod-cone degeneration in dogs | |
WO1997006276A1 (fr) | Test co-dominant de diagnostic genetique | |
WO1997031011A1 (fr) | Marqueurs microsatellites permettant d'identifier des maladies ou des traits genetiques canins | |
WO1986005512A1 (fr) | Sonde adn destinee au diagnostic antenatal de certaines anomalies chromosomiques | |
US5691144A (en) | Methods of detecting novel mutations relating to X-linked Charcot-Marie-Tooth disease | |
US6998235B2 (en) | Method of determining susceptibility to bipolar disorders | |
Saker | The molecular genetics of Type 2 diabetes | |
CA2390670C (fr) | Methode de determination de la susceptibilite aux troubles bipolaires | |
Barcellos | Genetic analysis of multiple sclerosis in Caucasian and Northern Chinese populations: An investigation of HLA and non-HLA loci | |
Alrashed | Molecular Genetic Basis of Recessively Inherited Retinal Dystrophies in the Saudi Population | |
Malenfant | Genomic Rearrangements in Autism Spectrum Disorders: Identification of Novel Candidate Genes | |
RAZA | Genetic Studies on stuttering families | |
Vaughan | Genetic susceptibility in Parkinson's disease | |
Negura et al. | Identification of rare intronic variants defining novel BRCA haplotypes | |
Tapscott | Brain Transcript Levels and Co-Segregation of the Prdm2 Gene with Ethanol Preference in Mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2292795 Country of ref document: CA Ref country code: CA Ref document number: 2292795 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998929511 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09424949 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1999501759 Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1998929511 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998929511 Country of ref document: EP |